title: Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies.
abstract: The previous decade has witnessed remarkable advances in our understanding and treatment of chronic lymphocytic leukemia. Chemoimmunotherapy has provided patients with unprecedented remission rates and has improved survival compared to chemotherapy alone. However, the availability of targeted therapies and monoclonal antibodies argues for exploring non-cytotoxic and biologic regimens for this disease. In this article, we review available targeted and non-chemotherapeutic agents for CLL, attempting to position these therapies in the treatment paradigm of CLL in the era of risk stratification as we move forward.
authors.affiliation: Department of Medicine, Division of Hematology and Oncology, Advocate Lutheran General Hospital, Park Ridge, IL 60068, USA. cnabhan@oncmed.net
authors.forename: Chadi
authors.initials: C
authors.lastname: Nabhan
authors.forename: Neil
authors.initials: N
authors.lastname: Dalal
authors.forename: Jayesh
authors.initials: J
authors.lastname: Mehta
authors.forename: Neil E
authors.initials: NE
authors.lastname: Kay
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001688:Biological Products / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004358:Drug Therapy / Q000379:methods / Q000639:trends*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D059016:Tumor Microenvironment / Q000187:drug effects / Q000502:physiology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D001688:Biological Products; D004338:Drug Combinations